{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:02:43Z","timestamp":1791374563815,"version":"4.3.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013281","name":"Joint Programming Initiative on Antimicrobial Resistance","doi-asserted-by":"publisher","award":["8th call for networks"],"award-info":[{"award-number":["8th call for networks"]}],"id":[{"id":"10.13039\/100013281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives\/purpose<\/jats:title>\n                    <jats:p>The costs attributable to antimicrobial resistance (AMR) remain theoretical and largely unspecified. Current figures fail to capture the full health and economic burden caused by AMR across human, animal, and environmental health; historically many studies have considered only direct costs associated with human infection from a hospital perspective, primarily from high-income countries. The Global Antimicrobial Resistance Platform for ONE-Burden Estimates (GAP-ON\u20ac) network has developed a framework to help guide AMR costing exercises in any part of the world as a first step towards more comprehensive analyses for comparing AMR interventions at the local level as well as more harmonized analyses for quantifying the full economic burden attributable to AMR at the global level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>GAP-ON\u20ac (funded under the JPIAMR 8th call (Virtual Research Institute) is composed of 19 international networks and institutions active in the field of AMR. For this project, the Network operated by means of Delphi rounds, teleconferences and face-to-face meetings. The resulting costing framework takes a bottom-up approach to incorporate all relevant costs imposed by an AMR bacterial microbe in a patient, in an animal, or in the environment up through to the societal level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The framework itemizes the epidemiological data as well as the direct and indirect cost components needed to build a realistic cost picture for AMR. While the framework lists a large number of relevant pathogens for which this framework could be used to explore the costs, the framework is sufficiently generic to facilitate the costing of other resistant pathogens, including those of other aetiologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In order to conduct cost-effectiveness analyses to choose amongst different AMR-related interventions at local level, the costing of AMR should be done according to local epidemiological priorities and local health service norms. Yet the use of a common framework across settings allows for the results of such studies to contribute to cumulative estimates that can serve as the basis of broader policy decisions at the international level such as how to steer R&amp;D funding and how to prioritize AMR amongst other issues. Indeed, it is only by building a realistic cost picture that we can make informed decisions on how best to tackle major health threats.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13756-020-00822-6","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T07:03:40Z","timestamp":1606374220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["A one health framework to estimate the cost of antimicrobial resistance"],"prefix":"10.1186","volume":"9","author":[{"name":"the GAP-ON\u20ac network","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal M.","family":"Morel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Alm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"\u00c5rdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo M.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio L.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlieke E. A.","family":"de Kraker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiha","family":"Essack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Gonzalez-Zorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Guardabassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Harbarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souha S.","family":"Kanj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"Kostyanev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramanan","family":"Laxminarayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finola","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Levy","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Mendelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico T.","family":"Mutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Outterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus Rodriguez","family":"Ba\u0148o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Tacconelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7240-9567","authenticated-orcid":false,"given":"Luigia","family":"Scudeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"822_CR1","unstructured":"Transforming our world: the 2030 Agenda for Sustainable Development .:. Sustainable Development Knowledge Platform. https:\/\/sustainabledevelopment.un.org\/post2015\/transformingourworld. Accessed 11 Dec 2019."},{"key":"822_CR2","unstructured":"WHO. GLOBAL ACTION PLAN ON ANTIMICROBIAL' ' RESISTANCE. 2015."},{"key":"822_CR3","unstructured":"EU Commission. A European One Health Action Plan against Antimicrobial Resistance (AMR). https:\/\/ec.europa.eu\/health\/sites\/health\/files\/antimicrobial_resistance\/docs\/amr_2017_action-plan.pdf. Accessed 9 Oct 2020."},{"key":"822_CR4","volume-title":"Evaluation of the EC Action Plan against the rising threats from antimicrobial resistance","author":"E Smith","year":"2016","unstructured":"Smith E. Evaluation of the EC Action Plan against the rising threats from antimicrobial resistance. EU commission; 2016."},{"key":"822_CR5","unstructured":"Drug-Resistant Infections: A Threat to Our Economic Future. https:\/\/www.worldbank.org\/en\/topic\/health\/publication\/drug-resistant-infections-a-threat-to-our-economic-future. Accessed 25 Feb 2020."},{"key":"822_CR6","doi-asserted-by":"crossref","unstructured":"Food and Agriculture Organization of the United Nations. Antimicrobial Resistance. What is it? http:\/\/www.fao.org\/antimicrobial-resistance\/background\/what-is-it\/en\/. Accessed 9 June 2018.","DOI":"10.18356\/c4beb2a3-en"},{"key":"822_CR7","unstructured":"Cecchini M, Langer J, Slawomirski L. Antimicrobial Resistance' ' in G7 countries and beyond economic issues, Policies and Options for Action . OECD; 2015."},{"key":"822_CR8","volume-title":"Tackling antimicrobial resistance: ensuring sustainable R&D","author":"OECD, WHO, OIE, FAO","year":"2017","unstructured":"OECD, WHO, OIE, FAO. Tackling antimicrobial resistance: ensuring sustainable R&D. 2017."},{"key":"822_CR9","unstructured":"The Review on Antimicrobial Resistance, chaired by Jim O\u2019Neill. TACKLING DRUG-RESISTANT' ' INFECTIONS GLOBALLY: FINAL REPORT AND RECOMMENDATIONS. 2016."},{"key":"822_CR10","unstructured":"RAND corporation JT, Marco Hafner, Erez Yerushalmi, Richard Smith, Jacopo Bellasio, Raffaele Vardavas, Teresa Bienkowska-Gibbs, Jennifer Rubin. Estimating the economic costs of antimicrobial resistance. Model and Results. RAND corporation; 2016."},{"key":"822_CR11","unstructured":"The World Bank. Drug resistant Infections. A Threat to Our Economic Future (Discussion draft). The World Bank; 2016."},{"key":"822_CR12","unstructured":"GAP-ONE. https:\/\/www.jpiamr.eu\/gap-one\/. Accessed 30 Dec 2019."},{"key":"822_CR13","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208.","journal-title":"J Biomed Inform"},{"key":"822_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318\u201327. https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3.","journal-title":"Lancet Infect Dis"},{"key":"822_CR15","unstructured":"Background: About the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) - Canada.ca. https:\/\/www.canada.ca\/en\/public-health\/services\/surveillance\/canadian-integrated-program-antimicrobial-resistance-surveillance-cipars\/background.html. Accessed 3 June 2020."},{"key":"822_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1128\/CMR.00001-13","volume":"26","author":"V Schechner","year":"2013","unstructured":"Schechner V, Temkin E, Harbarth S, Carmeli Y, Schwaber MJ. Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. Clin Microbiol Rev. 2013;26:289\u2013307. https:\/\/doi.org\/10.1128\/CMR.00001-13.","journal-title":"Clin Microbiol Rev"},{"key":"822_CR17","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1089\/mdr.2017.0270","volume":"24","author":"M Corbella","year":"2018","unstructured":"Corbella M, Caltagirone M, Gaiarsa S, Mariani B, Sassera D, Bitar I, et al. Characterization of an outbreak of extended-Spectrum \u03b2-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit in Italy. Microb Drug Resist. 2018;24:1128\u201336. https:\/\/doi.org\/10.1089\/mdr.2017.0270.","journal-title":"Microb Drug Resist"},{"key":"822_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1017\/ice.2016.118","volume":"37","author":"GM Snyder","year":"2016","unstructured":"Snyder GM, Young H, Varman M, Milstone AM, Harris AD, Munoz-Price S. Research methods in healthcare epidemiology and antimicrobial stewardship-observational studies. Infect Control Hosp Epidemiol. 2016;37:1141\u20136. https:\/\/doi.org\/10.1017\/ice.2016.118.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"822_CR19","doi-asserted-by":"publisher","first-page":"20140085","DOI":"10.1098\/rstb.2014.0085","volume":"370","author":"FM Aarestrup","year":"2015","unstructured":"Aarestrup FM. The livestock reservoir for antimicrobial resistance: a personal view on changing patterns of risks, effects of interventions and the way forward. Philos Trans R Soc Lond B, Biol Sci. 2015;370:20140085. https:\/\/doi.org\/10.1098\/rstb.2014.0085.","journal-title":"Philos Trans R Soc Lond B, Biol Sci"},{"key":"822_CR20","unstructured":"WHO | Joint FAO\/WHO Expert Meeting in collaboration with OIE on Foodborne Antimicrobial Resistance: Role of the Environment, Crops and Biocides. https:\/\/www.who.int\/foodsafety\/publications\/Environment-Crops-and-Biocides\/en\/. Accessed 30 Dec 2019."},{"key":"822_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41893-018-0164-3","volume":"1","author":"Living with Resistance project","year":"2018","unstructured":"Living with Resistance project. Antibiotic and pesticide susceptibility and the Anthropocene operating space. Nat Sustain. 2018;1:632\u201341. https:\/\/doi.org\/10.1038\/s41893-018-0164-3.","journal-title":"Nat Sustain"},{"key":"822_CR22","unstructured":"Implications of alternative funding arrangements for NICE Appraisal. https:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic-resistant-bacteria\/en\/. Accessed 9 Oct 2020."},{"key":"822_CR23","unstructured":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. https:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic-resistant-bacteria\/en\/."},{"issue":"Suppl 2","key":"822_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/myc.12329","volume":"58","author":"P Mu\u00f1oz","year":"2015","unstructured":"Mu\u00f1oz P, Valerio M, Vena A, Bouza E. Antifungal stewardship in daily practice and health economic implications. Mycoses. 2015;58(Suppl 2):14\u201325. https:\/\/doi.org\/10.1111\/myc.12329.","journal-title":"Mycoses."},{"key":"822_CR25","doi-asserted-by":"publisher","unstructured":"Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A, et al. Candida auris: a review of the literature. Clin Microbiol Rev. 2018;31. https:\/\/doi.org\/10.1128\/CMR.00029-17.","DOI":"10.1128\/CMR.00029-17"},{"key":"822_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/cid\/civ885","volume":"62","author":"PE Verweij","year":"2016","unstructured":"Verweij PE, Chowdhary A, Melchers WJG, Meis JF. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of Mold-active antifungal azoles? Clin Infect Dis. 2016;62:362\u20138. https:\/\/doi.org\/10.1093\/cid\/civ885.","journal-title":"Clin Infect Dis"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00822-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13756-020-00822-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00822-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T07:40:55Z","timestamp":1606376455000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-020-00822-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1186\/s13756-020-00822-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-37343\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-37343\/v2","asserted-by":"object"}]},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]},"assertion":[{"value":"24 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MdK received funding from the Innovative Medicines Initiative Joint Undertaking under grant agreements nos. 115523, 115620, and 115737 (Combatting Bacterial Resistance in Europe projects [COMBACTE]), resources of which are composed of financial contribution from the European Union\u2019s 7th Framework Programme (FP7\/2007\u2009\u00b1\u20092013) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies\u2019 in kind contribution. CA as a part of EU-JAMRAI (European Union Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections) has received funding from the health programme of the European Union (2014-2020) under grant agreement N\u00b0761296.K.O. and R.A.A. was supported by the Cooperative Agreement Number IDSEP160030 from ASPR\/BARDA and by awards from Wellcome Trust, the Global AMR Innovation Fund (GAMRIF) funded by the UK Government Department of Health and Social Care (DHSC), the German Federal Ministry of Education and Research (BMBF) and the Bill & Melinda Gates Foundation, as administrated by CARB-X. The contents do not necessarily represent the views of the CARB-X project nor any CARB-X project funder including the governments of the United States (BARDA, NIAID), the United Kingdom (DHSC, GAMRIF), or Germany (BMBF), the Wellcome Trust, or the Bill & Melinda Gates Foundation. KO is also supported by the Social Innovation on Drug Discovery program at Boston University.None of the other Authors have conflicting interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}